Paul-Ehrlich-Institut

Go to:

Latest News - 09.04.2021

Lat­est News - 09.04.2021

Quick Links - Answers to most Frequently Asked Questions

  • Vaccinations for patients with allergies
    We provide a flow diagram to support your decision on whether you can receive a vaccination with an mRNA vaccine despite your allergy.
    Flowchart - Procedure in case of positive allergy history before COVID-19 mRNA vaccination (German only)
  • Very rare sinus vein thromboses following a COVID-19 vaccination with Vaxzevria from AstraZeneca
    The most frequently asked question on Vaxzevria currently is the question after which vaccination the very rare cases of sinus vein thromboses occurred. These cases were reported to the Paul-Ehrlich-Institut exclusively after the first vaccination (as per 24 March 2021). The most important information on Vaxzevria is provided under this link in condensed form:
    COVID-19 Vaccine AstraZeneca - Current Information at a glance

  • Composition of the COVID-19 vaccines
    The composition of the COVID-19 vaccines can be found in the appropriate SPCs and package leaflets. For all COVID-19 vaccines authorised in Germany, these can be viewed under this link:
    www.pei.de/covid-19-vaccines


If you are not sure whether you should refrain from receiving a vaccination due to an underlying disease, please consult your doctor for an information talk:

02.02.2021: Information sheet for vaccination against COVID-19 with mRNA vaccines
18.03.2021: Information sheet for vaccination against COVID-19 with vector vaccine

Updated: 09.04.2021

How we process your enquiry?

How we pro­cess your en­quiry?

anfragen@pei.de: This is the email address for health care professionals and individuals who wish to communicate with the Paul-Ehrlich-Institut.

Please send your enquiry either by a direct email or by using our contact form. Before sending an enquiry, please kindly check our website to find out whether it contains extensive information to answer your question.
( www.pei.de/faq-en, www.pei.de/coronavirus).

We may not be able to answer all email personally, since we are currently receiving a very high number of enquiries. For this reason, we are processing received emails using a special procedure to meet the currently extremely high amount of information needed by the health care professionals and the public to our best possible knowledge and ability:

  1. FAQ
    We view all incoming emails to check whether we already provide information on our website. If not, we will answer your enquiry personally. We will either send the answer to you directly or extend our information content on our website as soon as possible.
    www.pei.de/faq-en
    As a matter of course, we will answer urgent questions within the responsibility of the Paul-Ehrlich-Institut with priority.
  2. Quick links
    You can use our so-called quick links to obtain quick access to the most frequently asked questions. The information contained on this link is updated by us regularly.
    www.pei.de/quick-links-enquiries

  3. Focusing on tasks
    Please understand that we will be unable to provide personal answers to questions, as a standard procedure, if they are NOT within the direct sphere of responsibility of the Paul-Ehrlich-Institut.
    These include:

    • Vaccination recommendations
      In Germany, the organisation which makes recommendations on vaccinations is the Standing Vaccination Committee (Ständige Impfkommission, STIKO) at the Robert Koch-Institut. The STIKO extensively justifies its recommendations and provides them online:
      The COVID-19 vaccination recommendation by STIKO (German only)
    • Personal vaccination advice for citizens
      The Paul-Ehrlich-Institut is not a medical facility. Thus, we are unable to provide advice on vaccinations which goes beyond the assessment of reported suspected cases of adverse effects. If you require personalised advice on vaccinations, please always consult your treating doctor.
    • Recommendations on diagnoses and treatments
      Many factors are important for medical advice and a diagnosis. These can only be taken into account appropriately through personal contact between the patient and the doctor. For this reason, please seek advice from your treating doctor with regard to such questions. Please also refrain from sending us your personal patient data.

Sphere of responsibility of the Paul-Ehrlich-Institut related to vaccinations with COVID-19 vaccines

In its role as the Federal Institute for Vaccines and Biomedicines, the Paul-Ehrlich-Institut is responsible for the authorisation of clinical trials in Germany as well as pharmacovigilance – the documentation and assessment of possible adverse effects of COVID-19 vaccines, including those recorded during the post-marketing authorisation period. We actively contribute to the marketing authorisation of vaccines at a European level in the various bodies of the European Medicines Agency (EMA). In addition, we provide medicines developers with advice on regulatory affairs (scientific advice) and perform official batch release tests on COVID-19 vaccines.

Updated: 09.04.2021

Contact

Contact

Due to the coronavirus pandemic, the volume of requests has multiplied, so that we can only answer requests to a limited extent. In order to still serve as many request as possible, we are continuously expanding our range of information on the website. Please therefore check whether we have already prepared an answer on our website for your individual request:

Thank you for your understanding!

Important Note - Requests for medical (vaccination) advice

The Paul Ehrlich Institut is not a clinical institution and therefore cannot offer individual vaccination advice, except information regarding the evaluation of reported suspected cases of side effects.

Also, recommendations for diagnosis and therapy are not possible, because many factors are important for appropriate medical advice, which can only be adequately considered in the personal contact between doctor and patient.

Please contact your attending physician with these questions.

Your data

* Mandatory field

PEI Headquarter

PEI Head­quar­ter

Paul-Ehrlich-Institut
Federal Institute for Vaccines and Biomedicines
Paul-Ehrlich-Str. 51-59
63225 Langen
GERMANY

Phone: +49 6103 77 0
Email: pei@pei.de

Updated: 21.11.2019

Contact Persons

Con­tact Per­sons

Public

TopicEmail
Coronavirus Hotline for Public and Healthcare Professionals
Monday, Thursday and Friday: 10 a.m. to 1. p.m.
Tuesday and Wednesday: 2.p.m. to 5 p.m.
Phone: +49 6103 77 2222
The hotline does not offer individual vaccination advice, please contact your treating doctor.
anfragen@pei.de
Hotline for Questions from the Public and Healthcare Professionals
Tuesday: 2 p.m. to 5 p.m.
Thursday: 10 a.m. to 1 p.m.
Phone: +49 6103 77 1771
The hotline does not offer individual vaccination advice, please contact your treating doctor.
anfragen@pei.de
Requests for the Freedom of Information Act
[email protected]
Press Office
Phone: +49 6103 77 1030		presse@pei.de
Job Opportunities / Careerbewerbungen@pei.de
Contact Point Clinical Trials
For people involved in a clinical trial, their legal representative or one of their authorised representatives, pursuant to section 40 sub-section 5 AMG
Phone: +49 6103 77 1810
Fax: +49 6103 77 1277		klinpruefung@pei.de
German Haemophilia Registry
Phone: +49 6103 77 1860		dhr@pei.de
Biology Associationbiologischer-verein@pei.de
Representative of severely disabled persons
Christoph Stärk
Phone: +49 6103 77 1841		schwerbehindertenvertretung@pei.de

Regulatory Questions

TopicEmail
Innovation Office / Advice for Pharmaceutical Companiesinnovation@pei.de
Reference Material
Order of reference material for in vitro diagnostic medical devices (IVD)
Order of reference material for immunoglobulin preparations
Order of reference WHO Biological Reference Material

pei-ivd@pei.de
standard-igg@pei.de
whoccivd@pei.de
Central Office Preimplantation Genetic Diagnosis
Phone: +49 6103 4411		zpid@pei.de

Medicine Safety

TopicEmail
Pharmacovigilance
Fax: +49 6103 77 1263		pharmakovigilanz1@pei.de
Haemovigilance / Tissue Vigilance
Phone: +49 6103 77 3116 / 3117
Fax: +49 6103 77 1268		pharmakovigilanz2@pei.de
IVD-Vigilance
Phone: +49 6103 77 3114
Fax: +49 6103 77 1268		pharmakovigilanz2@pei.de
ATMP-Vigilance
Phone: +49 6103 77 3116 / 3117
Fax: +49 6103 77 1268		pharmakovigilanz2@pei.de
Pharmacovigilance (Veterinary)
Phone: +49 6103 77 1800
Fax: +49 6103 77 1279		vetmittelsicherheit@pei.de

Research

TopicEmail
Research Officer
science management, research infrastructure, research and development performance, promotion of young research fellows
PD--Private Lecturer Dr. Stephan Steckelbroeck
forschungsbeauftragter@pei.de

Adress

Paul-Ehrlich-Institut
Paul-Ehrlich-Strasse 51-59
63225 Langen
GERMANY

Updated: 18.03.2021